Efficacy and Safety of Finerenone Combined with Dapagliflozin in the Treatment of Non-Diabetic Chronic Kidney Disease: A Single-Center Retrospective Study.

Drug Des Devel Ther · 2026 · PMC13006183 · PMID 41878680

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

only marginally significantP = 0.080so close (0.05 < p ≤ 0.1)

However, after adjusting for UACR reduction, the direct effect remained only marginally significant (β = 5.88; 95% CI: –0.50 to 10.74; P = 0.080), and the path from UACR reduction to eGFR change was not significant (β = 0.00; 95% CI: –0.04 to 0.04; P = 0.871).

also in 5,076 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.